Gilead Sciences (GILD) Price to Sales (2009 - 2026)

Gilead Sciences (GILD) has reported Price to Sales for 18 consecutive years, with 20.09 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Sales rose 3.34% year-over-year to 20.09; the trailing twelve-month figure through Jun 2026 stood at 5.15 (up 7.9% YoY), and the FY2025 full-year result was 5.17, up 29.25% from the prior year.
• Price to Sales fell to 20.09 in Q2 2026 per GILD's latest filing, from 24.87 in the prior quarter.
• Across five years, Price to Sales topped out at 24.87 in Q1 2026 and bottomed at 10.99 in Q3 2022.
• Historically, Price to Sales has averaged 15.82 across 5 years, with a median of 14.53 in 2022.
• The sharpest annual moves came in 2024 and 2025: Price to Sales declined 16.26% in 2024, then surged 58.16% in 2025.
• Over 5 years, Price to Sales stood at 14.49 in 2022, then decreased by 2.07% to 14.19 in 2023, then climbed by 7.17% to 15.21 in 2024, then increased by 26.4% to 19.22 in 2025, then grew by 4.54% to 20.09 in 2026.
• According to Business Quant data, Price to Sales over the past three periods registered 20.09, 24.87, and 19.22 for Q2 2026, Q1 2026, and Q4 2025 respectively.